IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented ...
The STRIDE regimen's safety profile aligns with known medicine profiles, with no new safety signals. IMFINZI and IMJUDO are approved for advanced or unresectable HCC in multiple countries. Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and endocrinopathies, are noted, necessitating close monitoring and prompt management. Infusion-related reactions and complications post-HSCT are also highlighted. IMFINZI and IMJUDO are not recommended for pregnant or breastfeeding women.
Reference News
The STRIDE regimen's safety profile aligns with known medicine profiles, with no new safety signals. IMFINZI and IMJUDO are approved for advanced or unresectable HCC in multiple countries. Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, and endocrinopathies, are noted, necessitating close monitoring and prompt management. Infusion-related reactions and complications post-HSCT are also highlighted. IMFINZI and IMJUDO are not recommended for pregnant or breastfeeding women.